IR@PKUHSC  > 北京大学第三临床医学院  > 骨科
学科主题临床医学
Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo
Chen, Changbao1; Zhou, Hua1; Xu, Lanjun2,3; Xu, Dong2,3; Wang, Ying2,3; Zhang, Yingmei2,3; Liu, Xiaoguang1; Liu, Zhongjun1; Ma, Dalong2,3; Ma, Qingjun1; Chen, Yingyu2,3
关键词PDCD5 Apoptosis Chondrosarcoma Cisplatin Antitumor activity
刊名APOPTOSIS
2010-07-01
DOI10.1007/s10495-010-0489-5
15期:7页:805-813
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Biochemistry & Molecular Biology ; Cell Biology
研究领域[WOS]Biochemistry & Molecular Biology ; Cell Biology
关键词[WOS]GENE-EXPRESSION PROFILES ; INDUCED APOPTOSIS ; TUMOR-CELLS ; MYELOID-LEUKEMIA ; CANCER ; DEATH ; BCL-2 ; OVEREXPRESSION ; OSTEOSARCOMA ; PROGRESSION
英文摘要

Clinical management of chondrosarcoma remains a challenging problem, largely due to the toxicity and resistance of this tumor to conventional chemotherapy. Programmed Cell Death 5 (PDCD5) is a protein that accelerates apoptosis in different cell types in response to various stimuli, and has been shown to be down-regulated in many cancer tissues. In this study, mRNA and protein levels of PDCD5 were found to be up-regulated in cisplatin-treated SW1353 chondrosarcoma cells compared with untreated cells. Recombinant human PDCD5 (rhPDCD5) was also shown to sensitize chondrosarcoma cells to cisplatin-based chemotherapy, with inhibition of cell growth and apoptosis detected both in vitro and in vivo. Increased expression of Bax and decreased expression of Bcl-2 were also observed, along with release of cytochrome c from mitochondria into the cytosol. Additionally, cleavage of caspase-9 and caspase-3, as well as the cleavage of poly (ADP-ribose) polymerase (PARP), were detected, suggesting that sensitization of chondrosarcoma cells involves the intrinsic mitochondrial apoptosis pathway. In vivo, the treatment of a xenograft model of chondrosarcoma with rhPDCD5 and cisplatin significantly inhibited tumor cell proliferation and induced apoptosis compared to treatment with cisplatin alone. Overall, these data provide a theoretical basis for the administration of rhPDCD5 and cisplatin for the treatment of patients with chondrosarcoma.

语种英语
WOS记录号WOS:000279190700005
项目编号30871263 ; 30571870 ; 2009ZX09102-242 ; 2006AA02A305
资助机构National Natural Sciences Foundation of China ; National Key New Drug Creation Program of China ; National High Technology Research and Development Program of China
引用统计
被引频次:34[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/62096
专题北京大学第三临床医学院_骨科
北京大学基础医学院
作者单位1.Peking Univ, Hosp 3, Dept Orthopaed, Beijing 100191, Peoples R China
2.Peking Univ, Ctr Human Dis Genom, Beijing 100191, Peoples R China
3.Peking Univ, Sch Basic Med Sci, Lab Med Immunol, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Chen, Changbao,Zhou, Hua,Xu, Lanjun,et al. Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo[J]. APOPTOSIS,2010,15(7):805-813.
APA Chen, Changbao.,Zhou, Hua.,Xu, Lanjun.,Xu, Dong.,Wang, Ying.,...&Chen, Yingyu.(2010).Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo.APOPTOSIS,15(7),805-813.
MLA Chen, Changbao,et al."Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo".APOPTOSIS 15.7(2010):805-813.
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
Recombinant human PD(497KB)期刊论文出版稿开放获取CC BY-NC-SA浏览 请求全文
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Chen, Changbao]的文章
[Zhou, Hua]的文章
[Xu, Lanjun]的文章
百度学术
百度学术中相似的文章
[Chen, Changbao]的文章
[Zhou, Hua]的文章
[Xu, Lanjun]的文章
必应学术
必应学术中相似的文章
[Chen, Changbao]的文章
[Zhou, Hua]的文章
[Xu, Lanjun]的文章
相关权益政策
暂无数据
收藏/分享
文件名: Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。